Streetbeat News

Price Targets

CVCY

Piper Sandler analyst Andrew Liesch has assumed Central Valley Community (NASDAQ:CVCY) with an Overweight rating and set a price target of $19.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:44 am

RH

Loop Capital analyst Anthony Chukumba has downgraded RH (NYSE:RH) from Buy to Hold and set a price target of $300.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:42 am

WISH

Loop Capital analyst Laura Champine has downgraded ContextLogic (NASDAQ:WISH) from Hold to Sell and set a price target of $7.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:41 am

CFG

JP Morgan analyst Vivek Juneja has downgraded Citizens Financial Group (NYSE:CFG) from Overweight to Neutral and lowered the price target from $29 to $27.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:40 am

REAL

B of A Securities analyst Michael McGovern has upgraded RealReal (NASDAQ:REAL) from Underperform to Neutral and raised the price target from $1 to $1.85.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:39 am

SNDR

Susquehanna analyst Bascome Majors has upgraded Schneider National (NYSE:SNDR) from Neutral to Positive and announced a $33 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:38 am

AVXL

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Anavex Life Sciences (NASDAQ:AVXL) and maintained a $54 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:15 am

FWBI

HC Wainwright & Co. analyst Yi Chen has reiterated a 'Buy' rating on First Wave BioPharma (NASDAQ:FWBI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:14 am

CARM

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a 'Buy' rating on CARISMA Therapeutics (NASDAQ:CARM) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:13 am

ROIV

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $15 to $18.

Portfolio Pulse from richadhand@benzinga.com

June 29, 2023 | 10:13 am